Literature DB >> 1810184

Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.

D Fabre1, F Bressolle, R Gomeni, C Arich, F Lemesle, H Beziau, M Galtier.   

Abstract

A 30-min intravenous (i.v.) infusion of 200 mg of ciprofloxacin was administered twice daily to 12 patients with nosocomial pneumonia scheduled to undergo diagnostic fiberoptic bronchoscopy. The pharmacokinetics of ciprofloxacin were examined at the presumed steady state after 5 days of treatment. Eleven successive plasma samples were collected in the interval from 0 to 12 h after administration, and bronchial mucosa samples were taken 2 h after administration. Concentrations of drug in all samples were assayed by high-performance liquid chromatography with fluorimetric detection. The results showed that the kinetics in plasma did not differ from those determined previously in healthy volunteers. The mean concentrations in plasma peaked at 4.94 +/- 2.90 mg/liter at the end of infusion. The terminal half-life was 4.95 +/- 2.81 h, and the mean residence time 6.13 +/- 3.17 h. A large volume of distribution was calculated: 2.59 +/- 1.43 liters/kg. Mean total body clearance was 23.3 +/- 10.1 liters/h. The concentrations in bronchial mucosa reached 21.6 +/- 5.63 micrograms/g 2 h after drug intake. The tissue-versus-plasma concentration ratios ranged from 10.1 to 26.3 (mean value, 16.9 +/- 5.43). After 6 to 12 days of i.v. treatment, four patients were switched to oral ciprofloxacin. We propose a model for the simultaneous fit of the concentration-time curves obtained after i.v. infusion and oral dosing. The concentrations in tissue observed in this study were in excess of the MICs for bacteria considered to be susceptible to ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810184      PMCID: PMC245424          DOI: 10.1128/AAC.35.12.2521

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  [Mean residence time in the body. A new pharmacokinetic parameter?].

Authors:  A M Taburet; J L Steimer; D Doucet; E Singlas
Journal:  Therapie       Date:  1986 Jan-Feb       Impact factor: 2.070

2.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Multiple organ system failure and infection in adult respiratory distress syndrome.

Authors:  R C Bell; J J Coalson; J D Smith; W G Johanson
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

6.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Comparison of ciprofloxacin assays.

Authors:  A Weber; A L Smith; K Wong; B Painter; G Krol
Journal:  Methods Find Exp Clin Pharmacol       Date:  1988-02

8.  The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.

Authors:  D C Brittain; B E Scully; M J McElrath; R Steinman; P Labthavikul; H C Neu
Journal:  J Clin Pharmacol       Date:  1985-03       Impact factor: 3.126

9.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

10.  Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; C Baur
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  17 in total

1.  Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers.

Authors:  Manuela T Maya; Nuno J Gonçalves; Nuno E Silva; Augusto E Filipe; José A Morais
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

Review 2.  Drug treatment of pneumonia in the elderly: efficacy and costs.

Authors:  E Saltiel; S Weingarten
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

3.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

4.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

5.  Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa.

Authors:  Athanasios Chatzimoschou; Maria Simitsopoulou; Charalampos Antachopoulos; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.

Authors:  A Dalhoff
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 7.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

9.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 10.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.